Description of Tafero
Trade Name: Tafero Active Ingredient: Tenofovir Alafenamide (TAF) 25mg
Manufacture: Hetero Packing: Pack of 30 tablets
category: Anti-retroviral agent
Tafero tablet prohibits the multiplication of HIV (human retro virus) and chronic hepatitis B (HBV) virus in human cells. Thus prevents the hepatitis B and HIV virus from developing new viruses.
o TAFERO, an anti retroviral drug contains Tenofovir Alafenamide fumarate (TAF) as a active key ingredient.
o TAF is a nucleotide reverse transcriptase inhibitor (NRTI) which involves in the treatment of HIV infection and chronic hepatitis B infection.
o TAF is closely associated with reverse-transcriptase inhibitor Tenofovir disoproxil fumarate (TDF)
o Even if the TAF has a good drug safety profile and efficacy, it has some demerits like nephrotoxicity and which reduced bone mineral density.
Pharmacology of Tafero
Tafero Mechanism of Action:
Tafero contains an ingredient Tenofovir Alafenamide Fumarate; which is nucleotide reverse transcriptase inhibitor.
TAF is an ester prodrug of anti-retroviral, Tenofovir.
TAF is converted into tenofovir in vivo by using acyclic nucleoside phosphonate
Drug tenofovir decrease the normal DNA building blocks by lacking of OH molecules which is essential for phosphodiester bond linkage.
The phosphodiester bond linkage is responsible for DNA elongation
This leads to chain termination and prevents proviral DNA transcription.
The absorption of tablet Tafero is normally high. Tmax is monitored at 1 hour after oral administration of tablet Tafero
The volume of distribution is not available
Tenofovir Alafenamide fumarate is highly bound to plasma protein; nearly 80% of drug is bounds to protein.
TAF is hydrolyzed into Tenofovir which is occurs within the cells, it is a major metabolite.
Tenofovir is phosphorylated into active metabolite called tenofovir diphosphate.
Metabolism occurs by cathepsin A (Liposomal Protective Protein) in peripheral blood mononuclear cells and macrophages; and by Carboxyl esterase 1 (CES1) in hepatocytes.
The half life period of tablet Tafero is 0.51 hour.
Indication of Tafero
Tafero commonly used for the treatment of HIV infection and chronic hepatitis B infection (HBV).
Tafero involved in the treatment of chronic hepatitis (HCV) genotype I, II, III, IV, V &VI.
Dose & Dosage's of Tafero
If patient fail to take a dose of Tablet Tafero means, it should be taken within the time.
Patient should skip the dose and follow the regular drug dose schedule
Do not take two doses at the same time
Side Effects of Tafero
Tafero tablets Side effects:
Feeling sick and more.
Serious side effects like;
Mental/mood chances: depression, anxiety, confusion
Signs of kidney problems
Liver and blood problems
Allergic reactions: rash, itching/swelling, dizziness, trouble breathing.
An adverse effect occurs during the therapy;
Depression, asthenia, nausea, abdominal pain, insomnia, Pruritus, pyrexia
Pancreatitis, abdominal pain, elevated amylase, flatulence, dyspepsia, abdominal distension, elevated serum lipase
Lactic acidosis, severe hepatomegaly with steatosis, hypokalemia, and hypophosphatemia, elevated fasting cholesterol, elevated triglycerides
With an anti retroviral treatment: accumulation of body fat occurs, lead to obesity
Pruritus, lipodystrophy, angioedema, Eosinophilia,
Insomnia, depression, anxiety, abnormal dreams
Headache, dizziness, peripheral neuropathy, somnolence, paresthesia
Pyrexia, asthenia, fatigue, weight loss, chest pain, increased weight, procedural pain
Increased creatine kinase
Arthralgia, Myalgia, back pain, rhabdomyolysis, muscle weakness, myopathy, bone abnormalities, fractures, osteonecrosis, osteomalacia
Elevated transaminase elevated ALT, AST, hepatic steatosis, elevated liver enzymes
Increased creatinine, proximal renal tubulopathy (Fanconi syndrome), acute renal failure, acute tubular necrosis, nephrogenic diabetes insipidus, renal insufficiency, interstitial nephritis
Sinusitis, upper respiratory tract infection, Nasopharyngitis, pneumonia, pharyngolaryngeal pain, nasal congestion, dyspnea
Hematuria, glycosuria, decreased urine volume, Proteinuria, polyuria
Increased serum parathyroid hormone levels
Grave’s disease, polymyositis, Guillain-Barre syndrome
Contraindication of Tafero
The following conditions are contraindicated;
Softening of bones,
Low amount of phosphate in blood,
Elevation in blood acidity due to high levels of lactic acid,
Enlarged fatty liver,
Acute kidney failure,
Depletion of bone density,
Broken bone due to disease
Drug Interaction of Tafero
While patient administered Tafero with drugs which responsible for decreasing renal function or strive for active tubular secretion May leads to accumulating the concentration of Tenofovir. This may leads to aggravate the risk of adverse effects.
Carbamazepine, oxcarbazepine, Phenobarbital, phenytoin, rifabutin, rifampin and rifapentine: the effect of concentration of drug is decreased.
While co administrating with carbamazepine, the dose of tablet HepBest to be increased as two tablets once daily
There are 4 disease interactions occurs with tablet Tafero;
Precaution of Tafero
If patient having lactic acidosis and severe hepatomegaly with steatosis, care should be taken while that patient treated with Tafero (TAF)
Lactic acidosis/severe hepatomegaly with steatosis
Severe acute exacerbation of Hepatitis B after discontinuation of treatment
Risk of development of HIV-1 resistance in patient’s co infected with HBV and HIV-1
Usage & Safety profile of Tafero Pregnancy & Lactation
In both conditions, tablet Tafero is safe to use; but prior information given to physician in case of pregnancy condition.
There is a chance of placental transformation during labor
Pediatric and geriatric usage not recommended.
Storage of Tafero
Tafero is stored under temperature at 30oC (86oF).